Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
13/10/200912h40MarketwiredELNK, HERO, ABAT, NTAP, DBRN and ALTH Receives Analytical Coverage from WallStSense.comNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/10/200923h08Edgar (US Regulatory)Prospectus filed pursuant to Rule 424(b)(5) (424B5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/10/200912h19Edgar (US Regulatory)Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/10/200912h14Business WireAllos Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/10/200922h06Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/10/200922h01Business WireAllos Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/10/200913h00Business WireAllos Therapeutics Announces U.S. Availability of FOLOTYN™ (pralatrexate injection) for Relapsed or Refractory Peripheral T...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/10/200923h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/10/200912h36MarketwiredRothmanResearch.com Stock Review for SCG, CA, NE, MKC, COL and ALTHNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/09/200913h00Business WireAllos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/09/200922h15Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/200900h09Business WireAllos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN™ (pralatrexate) for the Trea...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/09/200912h00Edgar (US Regulatory)Notice of Effectiveness (EFFECT)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/200915h05Edgar (US Regulatory)Post-Effective Amendment to Registration Statement (POS AM)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/200914h00Business WireAllos Therapeutics to Hold Post Advisory Committee Conference CallNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/08/200915h31PR Newswire (US)Seven Summits Research Releases Comments on Boeing, Joy Global, Ciena Corporation, TakeTwo Interactive and Allos TherapeuticsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/08/200919h27Dow Jones NewsFDA Has Several Issues With Allos Data For FolotynNASDAQ:ALTHAllos Therapeutics Inc.
14/08/200922h16Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/08/200916h25Business WireAllos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Ref...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/08/200923h16Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/08/200922h00Business WireAllos Therapeutics Reports Second Quarter 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/07/200916h06Business WireAllos Therapeutics Launches Peripheral T-Cell Lymphoma WebsiteNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/07/200914h00Business WireAllos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/07/200914h04Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/07/200914h00Edgar (US Regulatory)Securities Registration Statement (simplified form) (S-3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/07/200914h07MarketwiredBridgewaterEquity.com Free Fundamental Sector & Market Research on OCR, GGC, NWD, MPW, ALTH and NEXMNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/07/200914h00Business WireAllos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/06/200914h40PR Newswire (US)InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren ResoNASDAQ:ALTH
02/06/200912h05Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/05/200914h00Business WireAllos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH